182 related articles for article (PubMed ID: 35467062)
1. Association of Nrf2 expression and mutation with Weiss and Helsinki scores in adrenocortical carcinoma.
Kamai T; Murakami S; Arai K; Ishida K; Kijima T
Cancer Sci; 2022 Jul; 113(7):2368-2377. PubMed ID: 35467062
[TBL] [Abstract][Full Text] [Related]
2. Lower expression of ATM and gene deletion is more frequent in adrenocortical carcinomas than adrenocortical adenomas.
Ye J; Qi Y; Wang W; Sun F; Wei Q; Su T; Zhou W; Jiang Y; Yuan W; Cai J; Cui B; Ning G
Endocrine; 2012 Jun; 41(3):479-86. PubMed ID: 22311173
[TBL] [Abstract][Full Text] [Related]
3. DNA and kinetic heterogeneity during the clonal evolution of adrenocortical proliferative lesions.
Blanes A; Diaz-Cano SJ
Hum Pathol; 2006 Oct; 37(10):1295-303. PubMed ID: 16949934
[TBL] [Abstract][Full Text] [Related]
4. Characterization of the mTOR pathway in human normal adrenal and adrenocortical tumors.
De Martino MC; Feelders RA; de Herder WW; van Koetsveld PM; Dogan F; Janssen JA; Waaijers AM; Pivonello C; Lamberts SW; Colao A; de Krijger RR; Pivonello R; Hofland LJ
Endocr Relat Cancer; 2014 Aug; 21(4):601-13. PubMed ID: 24891456
[TBL] [Abstract][Full Text] [Related]
5. Differential expression of microRNA-675, microRNA-139-3p and microRNA-335 in benign and malignant adrenocortical tumours.
Schmitz KJ; Helwig J; Bertram S; Sheu SY; Suttorp AC; Seggewiss J; Willscher E; Walz MK; Worm K; Schmid KW
J Clin Pathol; 2011 Jun; 64(6):529-35. PubMed ID: 21471143
[TBL] [Abstract][Full Text] [Related]
6. Microarray gene expression and immunohistochemistry analyses of adrenocortical tumors identify IGF2 and Ki-67 as useful in differentiating carcinomas from adenomas.
Soon PS; Gill AJ; Benn DE; Clarkson A; Robinson BG; McDonald KL; Sidhu SB
Endocr Relat Cancer; 2009 Jun; 16(2):573-83. PubMed ID: 19218281
[TBL] [Abstract][Full Text] [Related]
7. [Clinicopathologic features and expression of epidermal growth factor receptor and vascular endothelial growth factor in adrenocortical tumors].
Wang CP; Zhang J; Gao J; Liu PP; Wu SF; Zeng X; Liang ZY
Zhonghua Bing Li Xue Za Zhi; 2012 Oct; 41(10):686-90. PubMed ID: 23302311
[TBL] [Abstract][Full Text] [Related]
8. The molecular basis of adrenocortical cancer.
Lehmann T; Wrzesinski T
Cancer Genet; 2012 Apr; 205(4):131-7. PubMed ID: 22559973
[TBL] [Abstract][Full Text] [Related]
9. Diagnostic and prognostic assessments of adrenocortical carcinomas by pathological features, immunohistochemical markers and reticular histochemistry staining.
Gan W; Han X; Gong Y; Yang Y; Wang C; Zhang Z
Diagn Pathol; 2024 May; 19(1):71. PubMed ID: 38802933
[TBL] [Abstract][Full Text] [Related]
10. Molecular markers and the pathogenesis of adrenocortical cancer.
Soon PS; McDonald KL; Robinson BG; Sidhu SB
Oncologist; 2008 May; 13(5):548-61. PubMed ID: 18515740
[TBL] [Abstract][Full Text] [Related]
11. The computed tomography adrenal wash-out analysis properly classifies cortisol secreting adrenocortical adenomas.
Humbert AL; Lecoanet G; Moog S; Bouderraoui F; Bresler L; Vignaud JM; Chevalier E; Brunaud L; Klein M; Cuny T
Endocrine; 2018 Mar; 59(3):529-537. PubMed ID: 29332161
[TBL] [Abstract][Full Text] [Related]
12. Distinguishing adrenal cortical carcinomas and adenomas: a study of clinicopathological features and biomarkers.
Wang C; Sun Y; Wu H; Zhao D; Chen J
Histopathology; 2014 Mar; 64(4):567-76. PubMed ID: 24102952
[TBL] [Abstract][Full Text] [Related]
13. Clinically significant association of elevated expression of nuclear factor E2-related factor 2 expression with higher glucose uptake and progression of upper urinary tract cancer.
Nukui A; Narimatsu T; Kambara T; Abe H; Sakamoto S; Yoshida KI; Kamai T
BMC Cancer; 2018 May; 18(1):493. PubMed ID: 29716554
[TBL] [Abstract][Full Text] [Related]
14. Increased expression of Nrf2 and elevated glucose uptake in pheochromocytoma and paraganglioma with SDHB gene mutation.
Kamai T; Murakami S; Arai K; Nishihara D; Uematsu T; Ishida K; Kijima T
BMC Cancer; 2022 Mar; 22(1):289. PubMed ID: 35300626
[TBL] [Abstract][Full Text] [Related]
15. Adrenocortical carcinoma: review of the pathologic features, production of adrenal steroids, and molecular pathogenesis.
Nakamura Y; Yamazaki Y; Felizola SJ; Ise K; Morimoto R; Satoh F; Arai Y; Sasano H
Endocrinol Metab Clin North Am; 2015 Jun; 44(2):399-410. PubMed ID: 26038208
[TBL] [Abstract][Full Text] [Related]
16. Adrenal cortical neoplasms: a study of clinicopathological features related to epidermal growth factor receptor gene status.
Zhang J; Wang C; Gao J; Sun J; Zeng X; Wu S; Liang Z
Diagn Pathol; 2014 Jan; 9():19. PubMed ID: 24457059
[TBL] [Abstract][Full Text] [Related]
17. Suppression of Forkhead Box Protein O1 (FOXO1) Transcription Factor May Promote Adrenocortical Tumorigenesis.
Stenman A; Murtha T; Korah R; Carling T
Horm Metab Res; 2017 Aug; 49(8):631-637. PubMed ID: 28641336
[TBL] [Abstract][Full Text] [Related]
18. Characterization of differential gene expression in adrenocortical tumors harboring beta-catenin (CTNNB1) mutations.
Durand J; Lampron A; Mazzuco TL; Chapman A; Bourdeau I
J Clin Endocrinol Metab; 2011 Jul; 96(7):E1206-11. PubMed ID: 21565795
[TBL] [Abstract][Full Text] [Related]
19. Investigation of N-cadherin/β-catenin expression in adrenocortical tumors.
Rubin B; Regazzo D; Redaelli M; Mucignat C; Citton M; Iacobone M; Scaroni C; Betterle C; Mantero F; Fassina A; Pezzani R; Boscaro M
Tumour Biol; 2016 Oct; 37(10):13545-13555. PubMed ID: 27468715
[TBL] [Abstract][Full Text] [Related]
20. Expression of FSCN1 and FOXM1 are associated with poor prognosis of adrenocortical carcinoma patients.
Liang J; Liu Z; Wei X; Zhou L; Tang Y; Zhou C; Wu K; Zhang F; Zhang F; Lu Y; Zhu Y
BMC Cancer; 2019 Nov; 19(1):1165. PubMed ID: 31783819
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
